Alex W Tong
Affiliation: Baylor University Medical Center
- A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumorsJohn Nemunaitis
Mary Crowley Cancer Research Centers, Dallas, Texas, USA
Mol Ther 18:429-34. 2010..Seven patients fulfilled Response Evaluation Criteria in Solid Tumors (RECIST) definition for stable disease at day 56 after treatment. Telomelysin was well tolerated. Evidence of antitumor activity was suggested...
- Prospects for CD40-directed experimental therapy of human cancerAlex W Tong
Cancer Immunology Research Laboratory, Baylor Sammons Cancer Center, Baylor University Medical Center, Dallas, Texas 75246, USA
Cancer Gene Ther 10:1-13. 2003..This review summarizes recent findings on CD154 recombinant protein- and gene therapy-based tumor treatment approaches, and examines our understanding of the multifaceted molecular mechanisms of CD154-CD40 interactions...
- MicroRNA profile analysis of human prostate cancersA W Tong
Gradalis, Inc, Dallas, TX, USA
Cancer Gene Ther 16:206-16. 2009..Growth inhibition through the reconstitution of miRNAs is potentially applicable for experimental therapy of prostate cancer, pending molecular validation of targeted genes...
- Small RNAs and non-small cell lung cancerAlex W Tong
Cancer Immunology Research Laboratory, Baylor Sammons Cancer Center, 3500 Gaston Avenue, Dallas, TX 75246, USA
Curr Mol Med 6:339-49. 2006....
- Small interfering RNA for experimental cancer therapyAlex W Tong
Baylor University Medical Center, Baylor Sammons Cancer Center, Mary Crowley Medical Research Center, Research Laboratory, 3500 Gaston Avenue, Dallas, TX 75246, USA
Curr Opin Mol Ther 7:114-24. 2005....
- Hereditary inclusion body myopathy: single patient response to intravenous dosing of GNE gene lipoplexGregory Nemunaitis
Mary Crowley Cancer Research Centers, Dallas, TX 75201, USA
Hum Gene Ther 22:1331-41. 2011..Further assessment will involve a phase I trial of intravenous administration of GNE gene lipoplex in individuals with less advanced HIBM with more muscle function...
- Antitumor activity of an oncolytic adenoviral-CD40 ligand (CD154) transgene construct in human breast cancer cellsErica M Gomes
Cancer Immunology Research Laboratory and Department of Pathology, Baylor Sammons Cancer Center, Dallas, TX 75246, USA
Clin Cancer Res 15:1317-25. 2009..In this proof-of-principle study, we examined the breast cancer growth-regulatory activities of an oncolytic adenoviral construct carrying the CD40L transgene (AdEHCD40L)...
- Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patientsJohn Nemunaitis
US Oncology, Dallas, Texas 75246, USA
Cancer Gene Ther 10:341-52. 2003..Further investigation of ONYX-015, possibly with agents that may modulate replication activity, or duration of virus survival, is indicated...
- In vivo safety and antitumor efficacy of bifunctional small hairpin RNAs specific for the human Stathmin 1 oncoproteinAnagha P Phadke
Gradalis, Inc, Dallas, TX 75201, USA
DNA Cell Biol 30:715-26. 2011..5 μg; HED of <0.09 mg/kg) confirmed systemic safety of the therapeutic dose, hence supporting early-phase assessments of clinical safety and preliminary efficacy...
- Growth inhibition of human multiple myeloma cells by an oncolytic adenovirus carrying the CD40 ligand transgeneMargret S Fernandes
Cancer Immunology Research Laboratory, Baylor Sammons Cancer Center, Baylor University Medical Center, Dallas, TX 75246, USA
Clin Cancer Res 15:4847-56. 2009..The growth-inhibitory activity of recombinant CD40 ligand (CD40L) is well documented in human multiple myeloma (MM). We examined MM-targeted delivery of CD40L by a conditional replicative oncolytic adenovirus, AdEHCD40L...
- Systemic therapeutic gene delivery for cancer: crafting Paris' arrowAlex W Tong
Gradalis, Inc, Dallas, TX 75246, USA
Curr Gene Ther 9:45-60. 2009..Improvements in each of these respective areas of study have converged to yield promising in vivo results...
- miRNA profiling for diagnosis and prognosis of human cancerChris Jay
Murex Pharmaceuticals, Dallas, Texas, USA
DNA Cell Biol 26:293-300. 2007..The evaluation of miRNAs expression may also be of prognostic value, as best exemplified by the correlation of let-7 and mir-155 levels with disease survival in nonsmall cell lung cancer...
- Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patientsAlex W Tong
Baylor Sammons Cancer Center, Baylor University Medical Center, Dallas, TX 75246, USA
Mol Ther 11:160-72. 2005..Intratumoral delivery of INGN 241 induced apoptosis in a large volume of tumor and elicited tumor-regulatory and immune-activating events that are consistent with the preclinical features of MDA-7/IL-24...
- Hereditary inclusion body myopathy: single patient response to GNE gene Lipoplex therapyGregory Nemunaitis
Mary Crowley Cancer Research Centers, 1700 Pacific, Dallas, TX 75201, USA
J Gene Med 12:403-12. 2010..Afflicted patients have no therapeutic options. In preclinical testing, we have previously demonstrated the ability to correct GNE gene function and the safety of delivery of wild type GNE gene using a liposomal delivery vehicle...
- Oncolytic viruses for induction of anti-tumor immunityAlex W Tong
Gradalis, Inc Dallas, TX, USA
Curr Pharm Biotechnol 13:1750-60. 2012..We discuss the innate and adaptive immune activating events that may contribute to these clinical outcomes, and examine systemic delivery strategies to tilt the immunological balance from viral clearance to tumor elimination...
- Immunoglobulin M myeloma: evaluation of molecular features and cytokine expressionKartik Konduri
Baylor Charles A Sammons Cancer Center, 3535 Worth Street, Dallas, TX 75246, USA
Clin Lymphoma 5:285-9. 2005..Additional studies on patients with this rare tumor may provide further insight into the pathogenesis of bone disease in plasma cell dyscrasias...
- Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNAYu An Zhang
The Mary Crowley Medical Research Center, Dallas, Texas
Cancer Res 66:9736-43. 2006..These findings indicate that Internavec can generate a two-pronged attack on tumor cells through oncogene knockdown and viral oncolysis, resulting in a significantly enhanced antitumor outcome...
- Oncolytic Viral Delivery of Oncogene siRNAAlex Tong; Fiscal Year: 2006..unreadable] [unreadable]..